AstraZeneca Exanta NDA Filing Set For 2003; Cost-Effective Vs. Warfarin?
Executive Summary
AstraZeneca intends to position its anticoagulant Exanta (ximelagatran) as a cost-effective alternative to warfarin in the antithrombotic market
You may also be interested in...
AstraZeneca Exanta Liver Safety Is Key Approval Issue, Company Says
AstraZeneca's discussions with FDA over the safety profile of its investigational anticoagulant Exanta will center on elevated liver enzyme levels reported during clinical trials
AstraZeneca Exanta Liver Safety Is Key Approval Issue, Company Says
AstraZeneca's discussions with FDA over the safety profile of its investigational anticoagulant Exanta will center on elevated liver enzyme levels reported during clinical trials
AstraZeneca Crestor, Exanta Promotions Will Focus On Dosing Advantages
One of AstraZeneca's promotional messages for its statin Crestor (rosuvastatin) will likely focus on the ability of the 10 mg dose to achieve target cholesterol levels without the need for up-titration